Form 4 for IMVT Immunovant, Inc.
Accepted 2022-01-11 00:00:00 ET · period of report 2022-01-07 · accession 0001764013-22-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-01-11 | 2022-01-07 | IMVT | Butchko Julia G. | Chief Dev, Tech. Off | S - Sale | $7.25 | -55.3K | 289.5K | -16% | -$401.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-07 | S | D | 55,318 | $7.25 | 289,488 | D | — | — | (F1) On August 3, 2021, the holder was granted 285,306 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which 50% of these RSUs vested on January 1, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs. |